Drug Trial Radar · NCT06888362
Trial to Investigate GZ21T in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Aug 19, 2024
Primary completion
Mar 31, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Genzada Pharmaceuticals USA, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CTC Clinical Trial Consultants AB
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double-blind, randomised, placebo-controlled trial designed to evaluate safety, tolerability, and pharmacokinetics (PK) after topical administration of single ascending doses of GZ21T in healthy volunteers.
Conditions
- Actinic Keratosis
Interventions
GZ21TDrug
GZ21T cream is intended to be studied as a potential treatment for patients with actinic keratoses and other dermatologic conditions which may be amendable to the study treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AETime frame: Day 1 to Day 7
- Number of Reported Skin ReactionsTime frame: Day 1 to Day 7.
- Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Day 1 to Day 7.
- Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)Time frame: Day 1 to Day 7.
- Number of Participants With Clinically Significant Abnormal Laboratory Test Results (Haematology, Clinical Chemistry, Coagulation)Time frame: Day 1 to Day 7.
- Number of Participants With Clinically Significant Changes in Physical Examination Findings.Time frame: Day 1 to Day 7.
- Amount of Cream Absorbed After Single Dose Applications.Time frame: 0-2 hours after IMP administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CTC (Clinical Trial Consultants) AB
Uppsala, Sweden, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.